3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
11
Cancer Pain
11
Pain
9
Pain, Postoperative
5
Agnosia
5
Colorectal Neoplasms
3
Colonic Neoplasms
3
Neoplastic Cells, Circulating
2
Neoplasm Metastasis
2
Mucositis
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Inflammation
2
Head and Neck Neoplasms
2
Chronic Pain
2
Breakthrough Pain
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Supratentorial Neoplasms
1
Stomach Neoplasms
1
Signs and Symptoms
1
Sezary Syndrome
1
Reperfusion Injury
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Bevacizumab
3
Radiosurgery
2
Irinotecan
2
pembrolizumab
1
Vorinostat
1
Valproic Acid
1
Thalidomide
1
Temozolomide
1
Surveys and Questionnaires
1
Sorafenib
1
Sildenafil Citrate
1
Pliability
1
Nivolumab
1
Morphine
1
Methadone
1
Exercise
1
Equipment and Supplies
1
Eating
1
Carboplatin
1
Amifampridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neurologic Manifestations
×
Morphine
×
Clear all
NCT04475029
2023-09-13
METAMORF
University of Aarhus
Phase NA
Completed
114 enrolled